临床研究已经说明了肠道微生物与疾病之间的关联,然而,根本的问题仍然不清楚,我们如何才能普及这些知识。考虑到人体肠道微生物成分在维持整体健康方面的重要作用,重要的是要了解人类肠道的微生物多样性和改变的疾病状况。宏基因组学提供了一种以社区方式分析和理解微生物及其作用的方法。它提供定性和定量测量,就相对丰度而言。各种研究已经在进行,以找出微生物和疾病之间的联系;尽管如此,挖掘的知识是有限的。考虑到目前的情况,使用靶向宏基因组学方法,我们分析了来自健康和患病个体的99个样本的肠道微生物组。我们的宏基因组分析主要针对五个患病的微生物组(即,年龄相关性黄斑变性,自闭症谱系障碍,类风湿性关节炎,2型糖尿病和Vogt-Koyanagiharada),与健康的微生物组相比,并报道了不同条件下疾病相关微生物组的变化。
Clinical studies have already illustrated the associations between gut microbes and diseases, yet fundamental questions remain unclear that how we can universalize this knowledge. Considering the important role of human gut microbial composition in maintaining overall health, it is important to understand the microbial diversity and altered disease conditions of the human gut. Metagenomics provides a way to analyze and understand the microbes and their role in a community manner. It provides qualitative as well as quantitative measurements, in terms of relative abundance. Various studies are already going on to find out the association between microbes and diseases; still, the mined knowledge is limited. Considering the current scenario, using the targeted metagenomics approach, we analyzed the gut microbiome of 99 samples from healthy and diseased individuals. Our metagenomic analysis mainly targeted five diseased microbiomes (i.e., Age-related macular degeneration, Autism spectrum disorder, Rheumatoid arthritis, Type 2 diabetes and Vogt-Koyanagi harada), with compare to healthy microbiome, and reported disease-associated microbiome shift in different conditions.